Weekly BCI roundup — Week of 2026-02-14
Links
- CorTec announces successful second human implantation of Brain Interchange — Company announcement (Feb 10, 2026): second implantation in an FDA IDE stroke study at Harborview/UW Medicine.
- FDA Quality Management System Regulation (QMSR) final rule — Regulatory context: QMSR effective Feb 2, 2026.
- A Surgical Planning Pipeline for Human Implantable Brain-Computer Interfaces — medRxiv preprint (posted Feb 3, 2026): workflow standardization for planning and localization.
- Friend, not Foe: Lowered Tissue Reactivity to Long-Term Polyimide Implants — bioRxiv preprint (Feb 9 window): flexible polyimide vs stiff silicon, with lower lesion/reactivity signals for polyimide.
- Multi-Layer Brain-Mimicking Phantom for Replicating Dura and Pia Membrane Dimpling and Rupture Properties — bioRxiv preprint: tunable benchtop insertion-mechanics model (agarose + pre-stretched PVC dura analog).
- Polymer-based flexible multi-shank probes for simultaneous intracortical microstimulation and two-photon calcium imaging — bioRxiv preprint: flexible multi-shank stimulation with current-steering directionality gains.
- ONWARD enrolls first participant in Empower BP pivotal study (ARC-IM) — Adjacent implantable-neurotech signal for clinical and regulatory execution infrastructure.
Here’s what moved in implantable BCIs during Feb 1–14, 2026.
The most meaningful updates were not flashy demos. They were:
- clinical repeatability in humans, and
- design science that isolates what drives chronic failure (especially mechanics + material mismatch).
1) CorTec: second-in-human is a real milestone
CorTec reported a second successful implantation of its Brain Interchange platform in an FDA IDE stroke study at Harborview/UW Medicine.
That matters because many programs can do a first case; fewer can show repeatable workflow across additional participants. “Second-in-human” is often where teams prove the procedure can be operationalized, not just demonstrated.
2) Regulation is tightening around execution quality
FDA’s QMSR effective date (Feb 2, 2026) reinforces a broader trend: implantable, connected systems are expected to show mature quality systems and lifecycle discipline early, not after scale.
For implantable BCIs, this raises the floor for design controls, verification/validation traceability, and post-market readiness.
3) Preprints converged on one message: mechanics dominate chronic outcomes
Three early-February preprints point in the same direction:
- Polyimide vs silicon chronic response: flexible polyimide showed lower tissue reactivity/lesion burden than stiff silicon in long-term settings.
- Insertion mechanics phantom: a layered brain-mimicking phantom reproduced dimpling/rupture characteristics with lower variance, supporting faster bench screening before animal runs.
- Flexible multi-shank stimulation: polymer probes paired microstimulation with two-photon imaging and showed better spatial control using bipolar/current-steering paradigms.
Taken together, these are practical signals for implant design priorities: reduce mismatch, control insertion injury, and shape electric fields more selectively.
4) Adjacent signal: clinical infrastructure is expanding beyond cortical implants
ONWARD’s first participant in a pivotal ARC-IM study is not a brain implant milestone directly, but it reflects a useful ecosystem pattern: implantable neurotech teams are getting better at multicenter clinical execution and regulatory cadence.
That infrastructure tends to transfer across adjacent neuromodulation/BCI programs.
Thread that ties the week together
Early February 2026 looked like an “engineering maturity” window for implantable BCIs:
- more repeatable human execution,
- more controlled evidence on chronic design choices,
- and stronger regulatory/process expectations around how these systems are built and maintained.
That is exactly the substrate the field needs before headline-grabbing capabilities can matter at scale.